Implementation of biosurety systems in a Department of Defense medical research laboratory.

New biosurety regulations and guidelines were implemented in 2003 because of increased concern for the safety and security of biological select agents and toxins (BSAT) that may be used as weapons of mass destruction. Biosurety is defined as the combination of security, biosafety, agent accountability, and personnel reliability needed to prevent unauthorized access to select agents of bioterrorism. These new regulations will lead to increased scrutiny of the use of select biological agents in registered research laboratories, but the regulations may have unintended effects on cost, progress, and perceptions in programs previously considered part of the academic research community. We review the history of biosurety, evolving guidelines, implementation of the regulations, and impacts at the lead research laboratory for medical biological defense for the Department of Defense.

[1]  A. Friedlander,et al.  Vaccination against Anthrax with Attenuated Recombinant Strains of Bacillus anthracis That Produce Protective Antigen , 1999, Infection and Immunity.

[2]  R. Tauxe,et al.  A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. , 1997, JAMA.

[3]  Philip K. Russell,et al.  Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.

[4]  Philip K. Russell,et al.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 2000, JAMA.

[5]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Philip K. Russell,et al.  Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.

[7]  S. Welkos,et al.  Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. , 1998, Vaccine.

[8]  C E Haley,et al.  An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. , 1997, JAMA.

[9]  L. Smith,et al.  Development of vaccines for prevention of botulism. , 2000, Biochimie.

[10]  M. A. Olson,et al.  Development of engineered vaccines effective against structurally related bacterial superantigens. , 1998, Vaccine.

[11]  Thomas V Inglesby,et al.  Biosecurity: responsible stewardship of bioscience in an age of catastrophic terrorism. , 2003, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[12]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[13]  Scott R. Lillibridge,et al.  Public Health Assessment of Potential Biological Terrorism Agents , 2002, Emerging infectious diseases.

[14]  E. Thompson,et al.  DNA Vaccination with the Hantaan Virus M Gene Protects Hamsters against Three of Four HFRS Hantaviruses and Elicits a High-Titer Neutralizing Antibody Response in Rhesus Monkeys , 2001, Journal of Virology.

[15]  R. Johnston,et al.  Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. , 2000, Vaccine.

[16]  J. Ezzell,et al.  Current laboratory methods for biological threat agent identification. , 2001, Clinics in laboratory medicine.

[17]  Jonathan Y. Richmond,et al.  Biosafety in microbiological and biomedical laboratories , 1999 .

[18]  Philip K. Russell,et al.  Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.